I’ve met Jesus during June 2023. Jesus works at Bayer Pharmaceuticals currently as the Head of Business Disruption. Love Stranger Things, AcceleRed, TeamRed, Science4Berlin, STEM4Health, Hackathons, Biotech, Digital Health, Startups, Web3, Networking For Health, Science, Technology, Pharma, Exobiology, Space, Science Fiction, Germany, Cuba, you can connect with Jesus in LinkedIn: https://www.linkedin.com/in/yeysus/ Twitter: https://twitter.com/yeysus Web3: yeysus.eth/.tez/.near POAPs collections in Welook.io: Bayer: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/1 Bayer Haemophilia: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/24 Bayer R&D DS&AI: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/25 Bayer R&D DS&AI Posters Madrid: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/26 Bayer Hellas / Greece: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/27 Bayer Product Supply: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/28 Bayer Berlin: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/29 Bayer IT: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/30 Bayer R&D: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/31 Bayer Communities: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/32 Bayer Medical Affairs: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/33

With the aim of protecting more and more Greek patients, a new product in Cardiovascular Medicine is launched. KERENDIA is now available for patients with CKD & Type 2 Diabetes. Welcome to Bayer Hellas internal Kerendia launch event, focusing on educating & preparing the Sales Team for a successful product promotion in the Greek market. In this event, you familiarized yourselves with the promotional materials & the role plays. This is the first POAP related to a pharmaceutical product. If you received this POAP, you are a True Pioneer in the Web3 space. Bayer is proudly promoting innovative practices. https://www.bayer.com/en/poap-tc

I am a pharmacist from Rio de Janeiro-Brazil and I work as a computational chemist at Bayer since 2021 in the Computational Molecular Design department in Wuppertal. I work side by side with chemists on different projects using our digital tools to design small molecules that maybe one day will help patients! I am passionate about my work and I have the opportunity to also be part of the Steering Group for Transformation and Leadership in the Drug Discovery Science to help transforming the way we work and communicate.

Understanding how compounds affect the disease biology of patients, and which potential side effects could be expected, is one of the core challenges in drug discovery. Transcriptomics (RNA-seq) allows us to measure these compound effects via an unbiased readout of gene expression changes. While „conventional“ analysis of RNA-seq data yields insights into individual compound effects and similarities, deeper connections between principles of compound structure and transcriptome effect elude us. Insights into this connection would help us support project teams with data-driven decision making on compounds. In this pilot, we are bringing together a cross-functional team of colleagues from LST, CMD, SyMOL and DS&AI to tackle this challenge and build a toolkit to enable understanding of ​how compound structure relates to complex gene expression patterns​ and to explore common themes amongst structures or shared off-target/general perturbation effects. This toolbox will become the starting point for other efforts aimed at leveraging multi-omics data in understanding compound mechanism of actions. Artwork created using Stable Diffusion.

Scientific work in Pharma R&D requires a reliable high-quality body of data and knowledge. Bayer Pharma R&D has an extremely large amount of scientific data. The use of a Data Catalog significantly improves the findability of data and serves as a key pillar in the implementation of a comprehensive data strategy.